KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biogen (BIIB) Divestments (2021 - 2025)

Biogen has reported Divestments over the past 6 years, most recently at $56.7 million for Q4 2025.

  • Quarterly results put Divestments at $56.7 million for Q4 2025, up 121.63% from a year ago — trailing twelve months through Dec 2025 was -$205.4 million (up 21.63% YoY), and the annual figure for FY2025 was $56.7 million, down 60.82%.
  • Divestments for Q4 2025 was $56.7 million at Biogen, up from -$262.1 million in the prior quarter.
  • Over the last five years, Divestments for BIIB hit a ceiling of $990.3 million in Q2 2022 and a floor of -$990.3 million in Q4 2022.
  • Median Divestments over the past 4 years was $0.0 (2021), compared with a mean of -$25.7 million.
  • Peak annual rise in Divestments hit 1185.86% in 2022, while the deepest fall reached 3424.2% in 2022.
  • Biogen's Divestments stood at -$28.1 million in 2021, then tumbled by 3424.2% to -$990.3 million in 2022, then surged by 73.53% to -$262.1 million in 2024, then surged by 121.63% to $56.7 million in 2025.
  • The last three reported values for Divestments were $56.7 million (Q4 2025), -$262.1 million (Q4 2024), and -$990.3 million (Q4 2022) per Business Quant data.